Abcellera Biologics Inc ABCL

$12.27 -0.81 (-6.19%)

Valuation

Market cap
3,762,117,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,876,500
Avg volume
4,760,140
Day's range
$11.75 – $12.91
Shares out
306,611,000
Stochastic %K
43%
Beta
1.41
Analysts
Strong Buy
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Nov 1, 7:20 AM
$ABCL $MRNA $REGN $LLY $SLS $ABCL this might be my last normal tweet before biotech goes vertical i’m not a whistleblower. I don’t work at Lilly, Novo or any of the big labs but there is a massive shift happening in human biology right now. it’s sitting in press releases and almost nobody reads them the last 6 months alone: - a once-daily pill roughly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.6 months) Continue… Part 2 Follows 👇🏻
0 replies
Stocktradesmoon Nov 1, 7:17 AM
$ABCL $MRNA $REGN $LLY $SLS Part 2/2 $ABCL ABcellera 🔥 🔥!!! - a one-time gene editing infusion cut hereditary angioedema attacks 87%, and 62% of patients stayed attack-free and off all other prevention for 6 months - a one-time gene edit for cholesterol dropped LDL up to 62%, and it held for over a year - a personalized mrna vaccine beat keytruda alone in a 1,137 patient melanoma phase 3 - retatrutide hit ~28% weight loss in a phase 3 - an ai-designed drug entered phase 3 - a pill that regrows hair passed its second phase 3 - an immunotherapy that could let some rectal cancer patients skip surgery, chemo and radiation just got fda approved - a man lived 271 days off dialysis on a pig kidney - human cells were caught passing chromosome-sized chunks of DNA to their neighbors, and it changes how the neighbors behave we are on the verge of an era where the human body is a software problem and the update cycle gets shorter everyday stick around, its going to get weird bio/acc
0 replies
Stocktradesmoon Nov 1, 7:13 AM
$ABCL $MRNA $REGN $LLY $SLS
0 replies
Stocktradesmoon Nov 1, 12:34 AM
$ABCL ❤️ $MRNA $SLS $LLY $REGN ABcellera 🔥 🔥 UPGRADES!!! BOOM!! Price targets (👀New Upgrade Yesterday $21 Price 🎯 jefferies) 🔵 Truist Securities — $30 🔴 JonesTrading — $25 🟡 UBS — $18 🟢 JPMorgan — $17 🟣 BMO Capital — $15 🟠 Goldman Sachs — $13 🩵 Cantor Fitzgerald — $12 🩷 Stifel — $9 ABCL — ANALYST PRICE TARGETS (USD) Truist Securities: $12 → $30 (+150%) JonesTrading: $13 → $25 (+92.3%) UBS: $18 (New Coverage) JPMorgan: $17 (New Coverage) BMO Capital: $15 Goldman Sachs: $13 (New Coverage) Cantor Fitzgerald: $11 → $12 (+9.1%) Stifel: $8 → $9 (+12.5%) 👀🚨🔥JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics and set a price target of $25.00. She’s actually a very accurate Analyst!! So this is a STRONG SIGNAL $25’ssss!
0 replies
Stocktradesmoon Nov 1, 12:29 AM
$ABCL $MRNA $SLS $LLY $JNJ 🚨UPDATE: ABcellera 🔥 🔥!!! ABCL Q3 EARNINGS AND CLINICAL CATALYSTS $ABCL has announced its participation schedule for the November investor conference. I see this announcement as more than just a notice for an institutional investor event—it’s connected to the next clinical phase of ABCL635. In particular, we need to watch whether the 12-week data we’re ve all been waiting for will be unveiled during the November 9 earnings release, or if it will lead to a separate announcement afterward. 1. 👀Upcoming Key Schedule October 22 Poster presentation on ABCL635 Phase 1/2 clinical trial at the TMS 2026 Conference November 9 Q3 2026 Earnings Release and Conference Call 7:00 AM Korea Time on November 10 November 11 Stifel Healthcare Conference November 16 Jefferies Global Healthcare Conference Q4 2026 ABCL575 Phase 1 clinical results presentation scheduled By end of 2026 Expect 12-week data for ABCL635 and updates on subsequent clinical information
0 replies
Stocktradesmoon Nov 1, 12:27 AM
$ABCL $MRNA $SLS $LLY $AMGN 👀🔥🚨BUYING!!!..SEE You at $21 Price Target 🎯 before earnings November 9th. Followed by 2 conferences days Apart!!! 👀🔥Three signals I look for in a platform biotech: large partners signing, internal assets reaching the clinic, and a balance sheet that never forces a bad deal. $ABCL showed all three this summer. That combination is rare in small cap biotech.
0 replies
Stocktradesmoon Nov 1, 12:22 AM
$ABCL $MRNA $SLS $REGN $AMGN In my mind, $ABCL is already a blue-chip growth stock. I know what I hold. Many still don’t understand what’s coming. They will eventually.
0 replies
Stocktradesmoon Nov 1, 12:20 AM
$ABCL $MRNA $SLS $REGN $LLY $ABCL Jefferies analyst Roger Song initiated coverage of AbCellera with a Buy rating and $21 price target. ABCL635 is the first clinical proof that AbCellera is turning a proven antibody discovery engine into a promising clinical pipeline, says the analyst, who calls the stock "far more than a one asset story.
0 replies